ERBB2 and cancer: While monoclonal antibody inhibition is the cornerstone of HER2-positive cancer therapy, directly blocking the ATP phosphorylation of the intracellular tyrosine kinase domain and interrupting downstream signaling can also be achieved through the use of several oral, small-molecule TKIs.